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Background & Aims: Biliverdin and bilirubin were previously considered end products of heme catabolism; now, however, there is evidence for further degradation to diverse bioactive products. Z-BOX A and Z-BOX B arise upon oxidation with unknown implications for hepatocellular function and integrity. We studied the impact of Z-BOX A and B on hepatic functions and explored their alterations in health and cholestatic conditions. Methods: Functional implications and mechanisms were investigated in rats, hepatocytic HepG2 and HepaRG cells, human immortalized hepatocytes, and isolated perfused livers. Z-BOX A and B were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in acute and acute-on-chronic liver failure and hereditary unconjugated hyperbilirubinemia. Results: Z-BOX A and B are found in similar amounts in humans and rodents under physiological conditions. Serum concentrations increased $20-fold during cholestatic liver failure in humans (p \ 0.001) and in hereditary deficiency of bilirubin glucuronidation in rats (p \ 0.001). Pharmacokinetic studies revealed shorter serum half-life of Z-BOX A compared to its regio-isomer Z-BOX B (p = 0.035). While both compounds were taken up by hepatocytes, Z-BOX A was enriched $100-fold and excreted in bile. Despite their reported vasoconstrictive properties in the brain vasculature, BOXes did not affect portal hemodynamics. Both Z-BOX A and B showed dose-dependent cytotoxicity, affected the glutathione redox state, and differentially modulated activity of Rev-erba and Rev-erbb. Moreover, BOXes-triggered remodeling of the hepatocellular cytoskeleton. Conclusions: Our data provide evidence that higher-order heme degradation products, namely Z-BOX A and B, impair hepatocellular integrity and might mediate intra-and extrahepatic cytotoxic effects previously attributed to hyperbilirubinemia. Lay summary: Degradation of the blood pigment heme yields the bile pigment bilirubin and the oxidation products Z-BOX A and Z-BOX B. Serum concentrations of these bioactive molecules increase in jaundice and can impair liver function and integrity. Amounts of Z-BOX A and Z-BOX B that are observed during liver failure in humans have profound effects on hepatic function when added to cultured liver cells or infused into healthy rats. 
Introduction
Heme (iron protoporphyrin IX) serves as a prosthetic group in a variety of proteins involved in oxygen transport, redox reactions, and signaling. 1 When released extracellularly, labile heme acts as an alarmin 2 and cytotoxic agonist 3 that is encountered by scavenger systems. 4 Intracellular heme concentrations are tightly controlled by its enzymatic degradation via heme oxygenases (HO), 5 yielding the first-order degradation products biliverdin, ferrous iron, and carbon monoxide (CO). 6, 7 The induction of HO-1 reflects a hallmark of the cellular response to oxidative stress and confers tissue protection during infection and inflammation. 8, 9 Bilirubin, generated from biliverdin by biliverdin reductases, contributes to tissue integrity via its anti-oxidative properties. 10, 11 Nevertheless, above a certain threshold bilirubin including neurotoxicity and cholemic nephropathy. 12, 13 In conditions of oxidative stress, unconjugated bilirubin is oxidized to higher-order degradation products such as the major bilirubin oxidation end products (BOXes), in particular the regio-isomers Z-2-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)-acetamide (Z-BOX A) and Z-2-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)acetamide (Z-BOX B) 14 ( Fig. S1 ).
In subarachnoid hemorrhage, Z-BOX A and B mediate vasoconstriction, presumably via inhibition of large-conductance Ca 2+ -and voltage-dependent Slo1 potassium channels. 15, 16 However, systematic assessment of the role of these higher-order degradation products was hampered so far by a lack of analytical tools and BOXes of appropriate purity. [16] [17] [18] To enable the systematic assessment of biological fate and function, we recently established syntheses, 19, 20 purification, and sensitive analytics of Z-BOX A and B. 21 Given the central role of the liver in heme degradation, we studied pharmacokinetics and -dynamics of Z-BOX A and B and explored their impact on hepatic function.
Materials and methods

Preparation of BOXes
Z-BOX A and Z-BOX B were prepared via in vitro bilirubin oxidation and chemical synthesis as described. 19, 20 Isomer purity was confirmed by liquid chromatography, coupled to tandem mass spectrometry (LC-MS/MS) and nuclear magnetic resonance spectroscopy. Water solubility and partition constants (1-octanol/ water) were determined spectrophotometrically.
Quantification of BOXes
Simultaneous determination of Z-BOX A and B was achieved via LC-MS/MS. 21 To assess possible differences between Z-BOXes concentrations in serum and plasma preparations human serum and plasma samples were spiked with 80 or 300 nmolÁL À1 of both analytes and analyzed accordingly. Gallstones were extracted using acetonitrile/isopropanol/water (2/1/1, v/v/v; 10 llÁmg À1 concrement).
Human specimen collection
All biomaterials were collected after approval by the ethics committee of Jena University and with informed consent from all subjects or their legal representatives (3548-08/12; 2435-12/08; 3624-11/12; 2712-12/09; 2160-11/07; 4406-04/15). Plasma samples of 28 patients were obtained upon fulfilling diagnostic criteria for liver failure (acute, ALF, n = 9; acute-on-chronic, ACLF, n = 15; transplant failure, n = 4). Ten healthy volunteers served as controls.
Rodents
Male Wistar rats (286-539 g, Harlan Laboratories), homozygous Gunn rats (165-333 g, in-house breeding 22 ), and C57BL/6J mice (25-30 g, in-house breeding) were used with the approval of the institutional animal welfare committees (Thuringian State Office for Consumer Protection and Food Safety, Bad Langensalza, Germany, 02-001/11, 02-058/14; Animal Ethics Committee of the University of Groningen, Groningen, The Netherlands, DEC6660A) under isoflurane anesthesia.
PK/PD studies
Rats were catheterized via the right jugular vein to inject Z-BOX A and Z-BOX B (26.7 lgÁ(kg body weight) À1 in PBS containing 0.25% dimethyl sulfoxide, DMSO), the left carotid artery for blood sampling, and bile duct for bile collection. Urine was sampled before and 60 min after application.
Portal hemodynamics
Rat livers were perfused via the portal vein with carbogen-saturated Krebs Henseleit buffer (Biochrom, Berlin, Germany) containing 2 gÁL À1 glucose, using a body weight-adapted constant flow rate of 100 mlÁ(kg body weightÁmin)
À1
. Z-BOX A, Z-BOX B, or vehicle was individually administered to the main flow. In parallel to bile sampling, portal pressure was measured (TSD104A, 10 or 20 Hz, Biopac Systems, Goleta, CA, USA) and 0.01 Hz low-pass filtered (OriginLab, Northampton, USA). 
Cell culture
Quantitative real-time PCR (qPCR)
After RNA extraction (Trireagent) and retro-transcription (MMLV, Sigma, Austria), qPCR was performed using the SYBRgreen method (SYBR Select Master Mix; ABIprism 7500, ThermoFisher, Austria). Primer sequences are provided in Table S1 . 
Electrophoretic mobility shift assays
Fluorescence microscopy
Cells were fixed in 4% formaldehyde prior to staining with 4 0 ,6-diamidino-2-phenylindole (DAPI) and AlexaFluor 488 labeled phalloidin and studied on a LSM-780 laser scanning microscope (Zeiss, Jena, Germany).
Electron microscopy
Scanning electron microscopy was performed on LEO-1530 and LEO-1450VP instruments (Zeiss, Oberkochen, Germany). Cells were grown on glass cover slips and fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Samples were dehydrated in ascending ethanol concentrations, critical-point dried, and sputter coated with gold. Statistical image evaluation was conducted in 182 Â 124 lm display windows (n = 5 to 13).
Statistical analysis
Statistical analysis was carried out using SigmaPlot (Systat, Erkrath, Germany). Data (mean ± SEM) were analyzed by t test, one-way ANOVA using Holm-Sidak post hoc analysis, or the corresponding non-parametric tests if criteria were violated. Correlation analysis was assessed with Pearson's product moment. p values below 0.05 were considered significant.
For further details regarding the materials and methods used, please refer to the Supplementary material and the CTAT table.
Results
BOXes occur under physiological conditions and increase in cholestasis
Concentrations of Z-BOX A and B in the systemic circulation have not been investigated yet. Therefore, we first determined serum/ plasma concentrations of Z-BOX A and B in health, liver failure, and bilirubin conjugation failure ( 
Yield of the regio-isomers in vitro
To better interpret blood concentrations of both regio-isomers in the light of PK/PD data we assessed their relative yield upon in vitro degradation of bilirubin with hydrogen peroxide, which led to formation of 1.5% Z-BOX A and 0.8% Z-BOX B, respectively.
The regio-isomers Z-BOX A and B have different pharmacokinetics
We then investigated whether the two regio-isomers Z-BOX A and B exhibit distinct pharmacokinetics. After i.v. bolus injection of equimolar Z-BOX A and B into rats, the peak serum concentrations of both compounds were reached at $3.5 min ( Fig. 2A, B) . The serum disappearances exhibited clearly distinguishable distribution (a) and elimination (b) phases (inserts in Fig. 2A , B; Table. S2). Applying a two-compartment model, both compounds were dispersed in similar relative distribution volumes of $1.0 LÁkg 
BOXes are actively excreted into bile
Since Z-BOX A and B were cleared from the circulation after bolus injection, we asked whether biliary and urinary elimination occurred. We detected both compounds in the bile before and after i.v. bolus injection into rats. Notably, we found only trace amounts of these BOXes in corresponding urine samples of the same rats before (Z-BOX A Fig. 2A, D) . In contrast, Z-BOX B exhibited a different excretion profile and appeared at significantly lower peak concentrations in bile (371.7 ± 89.5 nmolÁL
À1
, measured 1.0 min after substance application; p = 0.0022, compared to Z-BOX A in bile; n = 5; Fig. 2D , E). To test whether the different excretion kinetics of Z-BOX A and B are due to competition between the regioisomers, we solely injected Z-BOX B into rats in separate experiments (n = 3). In such experiments, bile concentrations of Z-BOX B were significantly increased (areas under the curves: 44.9 ± 18.9 lmolÁL À1 Ámin vs. 8.72 ± 3.39 lmolÁL À1 Ámin, p = 0.047; n = 3 and 5), albeit the excretion profiles were not different from those obtained after equimolar application of both regio-isomers (Fig. 2E, inset) . Once the peak concentration of Z-BOX A was reached after i.v. bolus, the Z-BOX A concentrations in bile were consistently [30 times higher than in serum. Within $50 min after injection of both regio-isomers, the overall amounts of non-metabolized compounds excreted into bile ( ) were found in bile as well as in corresponding gallstones (Table S3 , Fig. S3 ).
Z-BOX A and B do not alter portal hemodynamics
As Z-BOX A and B induce vasoconstriction of cerebral vessels 15 and as heme increases portal resistance (Schleser et al., manuscript submitted) we hypothesized that Z-BOX A and B may alter portal hemodynamics. Isolated rat livers were perfused with Z-BOX A or B (Fig. 3A, B) . Notably, the portal pressure did not change during the administrations or in the wash-out periods (Z-BOX A, p = 0.38; Z-BOX B, p [0.12; referencing to baseline; n = 3).
Z-BOX A and B impair hepatocellular metabolism
We then asked whether Z-BOX A and B may affect hepatocellular integrity and metabolism. HepG2 cells responded to Z-BOX A and B with a dose-dependent increase of LDH release without significant differences between the regio-isomers (Z-BOX A, 
Morphological alterations are specific to hepatocytes
To confirm the Z-BOX A-specific effect in a second in vitro model, we investigated the bi-potent progenitor cell line HepaRG before and after terminal differentiation into its hepatocyte-like and biliary-like phenotypes. While undifferentiated HepaRG cells responded uniformly to Z-BOX A like HepG2, terminally differentiated HepaRG cells responded heterogeneously, depending on the particular phenotype. The morphology of the biliary-like phenotype, which served as an endogenous control, remained unaffected. The hepatocyte-like phenotype exhibited an altered morphology with a loss of cell-cell contacts and membrane blebbing (Fig. 5D ).
BOXes interfere with the cytoplasmic glutathione redox potential
As the structures of Z-BOX A and B suggest reactivity towards thiol groups, we explored whether these BOXes affect the hepatocellular glutathione redox state. Using the genetically encoded fluorescent redox sensor Grx1-roGFP2, 23 we demonstrated that Z-BOX A and B significantly shift the glutathione redox potential to a more oxidized state (as measured via the formation of disulfide bonds in the fluorescent sensor) (Fig. 6A, Fig. S5 ). Applying LC and high-resolution MS, we further documented the formation of glutathione mono-adducts of both Z-BOX A and B in vitro (Fig. 6B,  Fig. S6 ). The analyses revealed several successively eluting compounds with the same high-resolution mass. Tentative chemical structures and UV absorbance spectra of these adducts, which are similar to those of untransformed Z-BOX A and B, 19, 20 are depicted in Figs. S6 and S7. Notably, Z-BOX A showed 10-fold higher reactivity towards glutathione than Z-BOX B (Fig. 6B) . We also investigated whether Z-BOX A and B may increase lipid peroxidation in HepG2 cells (experimental details see Supplementary material). Direct incubations with these BOXes for 2 h did not result in significant changes of lipid peroxidation. After 24-h priming with Z-BOX A, the cells were (along with their changed morphology) less susceptible to oxidative stress, induced by tert-butylhydroperoxide (Fig. S8) . and HMGCR RNA expression were increased by Z-BOX B (p \0.001; n = 3), while Z-BOX A did not affect their expression; however, both BOXes repressed CYP7A1 (p \0.001; n = 3). We also performed electrophoretic mobility shift assays using revDR2 and its mutant variant abolishing Rev-erbs binding and cytosolic or nuclear extracts of HIH (Fig. 6D) . Nuclear extracts of control cells weakly bound to the revDR2, while Z-BOX A nuclear extracts showed a strong binding, which was lost with revDR2 mutant. Z-BOX B nuclear extracts revealed two potential complexes of high and low size. Incubation with the revDR2 mutant identified the lower size complex as specific. Moreover, binding specificity was underlined by super-shift assays using antibodies against Rev-erba or b and compared with the Rev-erba modulator SR8278 (Fig. 6E) . Nuclear extracts of cells incubated with SR8278 showed a complex bound to revDR2, at the same molecular size as the Z-BOX A complex. Z-BOX A nuclear extract bound to revDR2, while pre-incubation of the nuclear extract with Rev-erba antibody reduced binding -thus demonstrating that Rev-erba was part of the complex and that its binding increased after Z-BOX A treatment. Similarly, Z-BOX B nuclear extract bound to the revDR2 oligos, while preincubation of the Z-BOX B extracts with a Rev-erbb antibody abolished binding. Taken together, our results suggest that Z-BOX A acts as a modulator of Rev-erba activity by increasing its binding to specific DNA response elements and repressing its own expression, while Z-BOX B increased the binding of Rev-erbb and modulated gene expression of FADS2 and HMGCR.
Z-BOX
Discussion
The liver plays a key-role in heme catabolism, yielding equimolar amounts of biliverdin, ferrous iron, and carbon monoxide À each known to affect hepatic function or integrity. 28, 29 However, there is a lack of data on formation, fate, and function of higher-order heme degradation products, in particular, of the regio-isomers Z-BOX A and Z-BOX B.
Here, we characterize formation, kinetics, and impact of Z-BOX A and B on hepatic function and integrity.
We demonstrate similar basal concentrations of Z-BOX A and B in healthy humans, rats, and mice. Substantially higher concentrations were found in patients with liver failure and in the Gunn rat model of congenital hyperbilirubinemia. Hepatocytes differently interacted with the regio-isomers Z-BOX A and B, leading to significantly different serum half-lives and biliary excretion profiles. While both acted as partial agonists of Rev-erbs and showed similar cytotoxicity, only Z-BOX A, which was strongly enriched in bile, triggered a characteristic remodeling of the hepatocellular cytoskeleton. Consistent with the altered cytoskeletal morphology and the effects on the central transcriptional regulators Rev-erba and b that would suggest sustained impairment of excretory function, acute effects on bile production were observed in vivo (data not shown), but not in the isolated perfused liver preparation (Fig. 2G, H) , in which the concentration of BOXes and bile salts remain constant. In contrast to single bolus injections, continued presence of endogenous Z-BOX A and B in patients and the substantial enrichment primarily of Z-BOX A may anticipate even stronger BOXes-triggered hepatocellular and extrahepatic effects under cholestatic conditions. As such, the molecular identification of Rev-erba and b as targets of Z-BOX A and B is in line with their distinct pharmacokinetics. Rev-erbs are nuclear receptors coordinating lipid, glucose and bile acid synthesis, as well as phase I and II detoxification enzymes. 27 In addition, Rev-erbs are part of the circadian clock n c n n n c n n n n n c n c n c c n n ) that are prevented from fully activating Reverbs by Z-BOX A and B through competition for the ligand binding domain access, or by modification of the oxidative stress, leading to changes in key cysteine residues of the ligand binding domain. 35 Repression of CYP7A1 as rate-limiting enzyme of bile acid synthesis by both BOXes may be considered a potentially protective mechanism against cholestasis with associated bile acid toxicity. Furthermore, the molecular reactivity of Z-BOX A and B towards thiol groups was shown with respect to glutathione, which constitutes the major hepatocellular redox system. As Z-BOX A and B altered the glutathione redox state different from direct oxidants, e.g. hydrogen peroxide at the same concentration, we hypothesize that Z-BOX A and B differently interfere with the glutathione system. Z-BOX A and B did neither increase lipid peroxidation after direct application nor led to a sensitization towards oxidative stress in vitro. We thus conclude that the formation of higher-order heme degradation products contributes to the detoxification of reactive oxygen species (ROS), despite their interaction with GSH. Based on the cerebrovascular effects of BOXes, 14, 15 we hypothesized that they might induce vasoconstriction in the portal circulation, which was however not the case. Although an indepth interpretation of these divergent results in both vascular beds is beyond the scope of the present study, we propose that the nature of the effector cells, i.e. smooth muscle cells for the cerebrovascular effects and presumably hepatic stellate cells for the portal hemodynamics, might explain this discrepancy. Although BOXes might affect terminal portal venules, available evidence would point towards a primary action of heme 36 and first-order degradation products, in particular CO, 37 act primarily on hepatic stellate cells with a distinctly different contractile apparatus compared to smooth muscle cells. Hepatocytes reacted differently towards the regio-isomers Z-BOX A and B. The specificity for regio-isomers is distinctly demonstrated by the differential binding to Rev-erba and b, respectively. Furthermore, the pharmacokinetic characteristics of Z-BOX A and B showed significant differences in serum disappearance rates and biliary excretion.
The mechanism of bilirubin degradation through ROSmediated conversions has not been elucidated yet. Based on the different chemical yields of the regio-isomers after in vitro degradation of bilirubin, we assume that Z-BOX A is also formed in a twofold excess in vivo. The approximately twofold shorter serum half-live of Z-BOX A compared to Z-BOX B is expected to compensate these unequal production rates leading to similar equilibrium concentrations of both regio-isomers in the bloodstream as observed in the present study (Fig. 1) . We demonstrated in rats that elimination into the bile substantially contributes to the serum clearance, in particular of Z-BOX A. Although the baseline concentrations of Z-BOX B in bile were approximately four times higher than those of Z-BOX A, primarily Z-BOX A was excreted and strongly enriched in the bile after i.v. bolus administration. The fact that Z-BOX B concentrations were significantly higher if solely Z-BOX B was administered strongly indicates a competition between both regio-isomers. Although the mechanistic background for the preference of Z-BOX A remains to be elucidated, we conclude that the presence of Z-BOX A suppresses the excretion of its isomer, Z-BOX B. The serum disappearance of Z-BOX B without marked excretion of the unchanged molecule into bile strongly suggests further metabolic conversions prior to its elimination. The immediate and selective enrichment of Z-BOX A in bile illustrates the availability of suitable transport mechanisms to lower serum concentrations. It further supports the notion that higher concentrations, as required for the rearrangement of the canalicular cell pole, can be achieved locally in vivo. Human bile samples from patients subjected to cholecystectomy exhibited moderately higher concentrations of Z-BOX A compared to Z-BOX B, which is in contrast to the baseline concentrations of these compounds in the bile of rats. Beyond an altered composition of the pathologic bile samples, this discrepancy may be due to potential formation of these BOXes from heme-derived tetrapyrroles, intermediate bilirubin oxidation products, or intestinal microbiota.
To support hepatocellular excretion into bile, microvilli provide a surface enhancement on the canalicular pole to facilitate transporter insertion and substance delivery. 38 Upon Z-BOX A treatment, HepG2 cells reacted with the reorganization of their actin cytoskeleton, leading to formation of spherical cell bodies and loss of polarity. It is noteworthy that these effects were observed in the HepG2 cell line at substantially higher concentrations than those measured in patient plasma. However, the substantial ($100-fold) enrichment of Z-BOX A across the hepatocellular route of excretion as well as the very long exposure intervals under conditions of cholestasis support the potential biological significance of alterations in brush border morphology. This effect was confirmed in a second cell line, i.e. terminally differentiated HepaRG cells, where the biliary-like phenotype represented an endogenous control. 39 The diverging reactivity of these two phenotypes towards Z-BOX A treatment is consistent with the presence of specific up-take systems for Z-BOX A that seem to be restricted to the hepatocyte-like phenotype. Hepatocellular stress induced by BOXes may impair bile secretory function. Interestingly, such cholestatic effects of BOXes may resemble cholestatic liver and bile duct injury induced by precursors of heme, in particular, protoporpyrins accumulating due to hereditary absence or chemical inhibition of ferrochelatase activity in humans with or mouse models of erythropoietic protoporphyria. 40 In summary, we demonstrate that Z-BOX A and B are bioactive endogenous degradation products of heme that differently interact with the liver. Consequently, our data introduce the concept that cytotoxic effects so far solely attributed to bilirubin might, at least in part, be mediated by higher-order degradation products of heme.
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